64.40CHF+3.79%Mkt Cap: —P/E: —1d ago
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value748.53M $
Revenue (TTM)265.22M $
Gross Profit99.48M $
Net Income (TTM)45.93M $
Revenue/Share21.67 USD
Last Price64.40 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees189
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA12.13
EV/Revenue2.82
P/S—
P/B5.61
EPS (TTM)-0.58
EPS (Forward)—
52W Range
57.5496% of range64.70
52W High64.70 CHF
52W Low57.54 CHF
Profitability
Gross Margin37.51%
Oper. Margin21.70%
EBITDA Margin23.27%
Profit Margin17.32%
ROE38.52%
ROA12.10%
Growth
Revenue Growth-2.90%
Earnings Growth-55.20%
Cash Flow & Leverage
Operating CF70.86M $
CapEx (TTM)—
FCF Margin21.15%
FCF Yield—
Net Debt-80.55M $
Net Debt/EBITDA-1.31
Balance Sheet
Debt/Equity69.73
Current Ratio5.12
Quick Ratio4.53
Book Value/Sh10.41 CHF
Cash/Share13.00 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.10.87M
Float12.21M
Insiders0.62%
Institutions30.88%
Technical
SMA 5035.23 (+82.8%)
SMA 20039.55 (+62.8%)
Beta0.41
S&P 52W Chg20.80%
Avg Vol (30d)9.01K
Avg Vol (10d)2.97K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—